The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined its C5 complement development strategy in an investor roundtable focused on cemdisiran, an siRNA targeting C5, and pozelimab, a C5-targeting antibody ...

InterSystems, a creative data technology provider powering more than one billion health records globally, today announced the launch of InterSystems Regional Health Connections, a new offering ...

A composable architecture that keeps customer data in-country from day one and outlasts the components inside it.

CloudFirst Divestiture -- The sale of the CloudFirst business closed on September 11, 2025, for $40 million, removing an ...

A rolling NDA has been initiated for tinlarebant in STGD1, potentially positioning the first disease-modifying systemic ...

April 7 (Reuters) - Fox Corp said on Tuesday it will integrate Kalshi's prediction market data across its news and streaming ...

A new grant from the American Cancer Society (ACS) will fund research into a new strategy for targeting glioblastoma at MUSC ...

Positive high-level results from a prespecified interim analysis of the I CAN Phase III trial showed that Ultomiris (ravulizumab) met its primary ...

Annexon Biosciences (NASDAQ:ANNX) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s ...

You’ll find the blue ingredient in serums and creams.

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG ...